[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610473":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":25,"locations":34,"responsibleParty":47,"collaborators":25,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":25,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":25,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":72,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Duke University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ESP + Liposomal Bupivacaine","EXPERIMENTAL","Group 1 receives ESP block with 0.5% bupivacaine plus liposomal bupivacaine.",[13],"Drug: ESP Block with Bupivacaine + Liposomal Bupivacaine",{"label":15,"type":10,"description":16,"interventionNames":17},"ESP + Plain Bupivacaine","Group 2 receives ESP block with 0.5% plain bupivacaine.",[18],"Drug: ESP Block with Bupivacaine",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ESP Block with Bupivacaine","Cervical and lumbar ESP blocks performed under ultrasound guidance using plain bupivacaine.",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"ESP Block with Bupivacaine + Liposomal Bupivacaine","Cervical and lumbar ESP blocks performed under ultrasound guidance using bupivacaine admixed with liposomal bupivacaine.",[9],[31],{"name":32,"affiliation":5,"role":33},"Stephen Davies","PRINCIPAL_INVESTIGATOR",[35],{"facility":5,"status":25,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":25},"Durham","North Carolina","27710","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-78.89862,35.99403,{"lat":45,"lon":44},{"type":48,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100610473","phase-4-esp-blocks-for-posterior-spinal-fusion-100610473",false,"NCT07228039","ESP Blocks for Posterior Spinal Fusion","A Double-Blind Prospective RCT Assessment of ESP Blocks for Analgesia Following Posterior Spinal Fusion","Inclusion Criteria\n\n* English speaking\n* Age 18-75\n* ASA physical status 1-3\n* Undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels)\n\nExclusion Criteria\n\n* Age \\\u003C18 or \\>75\n* ASA IV or V\n* Non-English speaking\n* BMI \\>40\n* Opioid dependence\n* Chronic pain\n* Anticoagulation or coagulopathy\n* Injection site infection\n* Hepatic or renal insufficiency\n* Allergy to study drugs\n* Pregnancy\n* Inability to communicate with investigators","ALL","18 Years","75 Years",{"count":60,"type":61},75,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.",[67],"Postoperative Pain",[69,70,71],"ESP Block","Spinal Fusion","Multimodal Analgesia","NOT_YET_RECRUITING","2026-06-17",{"date":75,"type":76},"2026-06-22","ACTUAL",{"date":78,"type":61},"2026-07",{"date":80,"type":61},"2028-01",{"name":5,"class":6},1]